Maravai LifeSciences
Supplies nucleic-acid tools and biologics testing products for therapies, vaccines, diagnostics, and research.
Something off on this page? Send us feedback.
Profile
Sells TriLink nucleic-acid products and Cygnus biologics safety testing tools to biopharma, diagnostics, and research customers. The business is concentrated in North America but also serves Asia Pacific and EMEA, with demand shaped by mRNA programs, biologics manufacturing workflows, and CleanCap order cycles.
Operates through TriLink and Cygnus, with customer-facing brands including TriLink BioTechnologies, Glen Research, Cygnus Technologies, and Alphazyme. TriLink covers RNA synthesis, mRNA production, CleanCap capping technology, oligonucleotide reagents, enzymes, and CDMO services; Cygnus covers biologics safety testing, impurity analytics, and viral-clearance products.
Serves global biopharma, emerging biotech, diagnostics, and research customers from a revenue base concentrated in North America, with additional sales in Asia Pacific and EMEA. The portfolio fits regulated drug-development workflows where reagent quality, assay specificity, and manufacturing support matter.
Demand depends on nucleic-acid therapy activity, biologics manufacturing pipelines, and uneven CleanCap orders tied to commercial vaccine programs. Recent operations also reflect a cost-structure reset under new leadership.
Company facts
Categories
Key statistics
Year to date +125% · Average volume (30d) 3.6M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 8, 2026 | Deutsche Bank | Target | $25 | $6 | ||
| Dec 15, 2025 | Wells Fargo | Reiterate | Overweight | $4.50 | ||
| Feb 26, 2025 | Baird | Downgrade | Outperform | Neutral | ||
| Dec 5, 2024 | Goldman Sachs | Downgrade | Neutral | Sell | ||
| Nov 8, 2024 | William Blair | Downgrade | Outperform | Market Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.04 | −$0.02 | +54.1% | $48.7M | $51.4M | +5.7% | −0.32% |
| May 7, 2026Q1 FY26 | −$0.05 | $0.01 | +120.0% | $53.0M | $65.8M | +24.2% | +23.10% |
| Feb 25, 2026Q4 FY25 | −$0.07 | −$0.04 | +42.9% | $49.0M | $49.9M | +1.7% | +9.20% |
| Nov 6, 2025Q3 FY25 | −$0.06 | −$0.08 | −33.3% | $49.1M | $41.6M | −15.1% | −0.69% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $46.9M | $47.4M | $41.6M | $49.9M | $65.8M | $51.4M | |
| Gross profit | $7.7M | $7.8M | $5.7M | $12.2M | $33.7M | $20.7M | |
| Operating income | −$49.2M | −$66.3M | $115.4M | −$6.7M | $2.5M | −$15.1M | |
| Net income | −$29.9M | −$39.6M | −$25.6M | −$35.7M | −$3.7M | −$12.4M | |
| Diluted EPS | −$0.21 | −$0.27 | −$0.18 | −$0.25 | −$0.03 | −$0.08 | |
| Gross margin | 16.5% | 16.4% | 13.6% | 24.5% | 51.2% | 40.1% | |
| Operating margin | -104.9% | -139.8% | 277.3% | -13.5% | 3.8% | -29.3% |
Fiscal years (4-quarter sums)FY21 $799.2M · FY22 $883.0M · FY23 $288.9M · FY24 $259.2M · FY25 $185.7M
Revenue by product · Q1 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $70.1M · Total debt $176.7M · Total assets $603.7M · Shareholders' equity $204.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 145.10M · Float 101.51M · 70.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| GTCR LLC | 20.15M | 13.89% | 13F | May 15, 2026 |
| Braidwell LP | 10.24M | 7.06% | 13F | May 15, 2026 |
| BlackRock, Inc. | 9.35M | 6.44% | 13F | May 13, 2026 |
| Hudson View Holdings LLC | 7.34M | 5.01% | 13G | May 14, 2026 |
| 12 West Capital Management LP | 7.26M | 5.00% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 10, 2026 | Kurt Oreshack | officer: General Counsel | −25,000 | $5.10 |
| Jun 9, 2026 | Kurt Oreshack | officer: General Counsel | −25,000 | $5.06 |
| Dec 5, 2025 | Gregory T. Lucier | director | +51,472 | $3.70 |
| Dec 8, 2025 | Gregory T. Lucier | director | +48,528 | $3.67 |
| Nov 13, 2025 | Bernd Brust | director, officer: Chief Executive Officer | +216,212 | $3.25 |
Peers
- Danaher
Broad genomic-medicine scale rival through Aldevron and IDT
- Thermo Fisher Scientific
Large life-science tools rival in mRNA, oligos, and enzymes
- Agilent Technologies
Therapeutic oligo CDMO rival with expanding nucleic-acid capacity
- Bio-Rad Laboratories
Bioprocess assay and HCP workflow rival for Cygnus
- Twist Bioscience
Synthetic DNA and long-oligo scale rival
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Maravai LifeSciences | $7.79 | +1.74% | $2.12B | — | — | 10.2 | +8.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Twist Bioscience | $141.01 | −0.20% | $8.80B | — | — | 20.4 | +23.3% |
| Median | 35.9 | 24.1 | 5.9 | +8.1% |